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suppress the replication of the hepatitis B virus (HBV) genome
in human hepatocytes, but they do not reduce the abundance
of viral proteins. The present study focused on effectively reduc-
ing viral protein levels.
Methods:We designed siRNAs (HBV-siRNA) that target
consensus sequences in HBV genomes. To prevent the emergence
of escaped mutant virus, we mixed three HBV-siRNAs
(HBV-siRNAmix); the mixture was encapsulated in a novel
pH-sensitive multifunctional envelope-type nanodevice (MEND),
a hepatocyte-specific drug delivery system. Coagulation factor 7
siRNA was used to assess delivery and knockdown efficiencies
of MEND/siRNA treatments in mice. The potency of MEND/
HBV-siRNAmix was evaluated in primary human hepatocytes
and in chimeric mice with humanized liver persistently infected
with HBV.
Results: Effective knockdown of targets, efficient delivery of
siRNA, and liver-specific delivery were each observed with
MEND. MEND/HBV-siRNA caused efficient reduction of HBsAg
and HBeAg in vitro and in vivo. However, ETV treatment did not
efficiently reduce HBsAg or HBeAg when compared with a singleJournal of Hepatology 20
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effects of a single dose of MEND/HBV-siRNAmix persisted for
14 days in vitro and in vivo.
Conclusion:We demonstrated that MEND/HBV-siRNA controlled
HBV more efficiently than did ETV. Furthermore, the effect of a
single dose of MEND/HBV-siRNA persisted for a long time. These
results indicated that MEND/HBV-siRNA may be a promising
novel HBV treatment that is more effective than reverse tran-
scriptase inhibitors.
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Hepatitis B virus (HBV) is a noncytopathic, hepatotropic virus of
the Hepadnaviridae family that causes either acute or chronic
hepatitis in humans [1]. Chronic infection is mostly asymp-
tomatic, but HBV carriers are at risk of developing cirrhosis and
hepatic carcinoma [2]. Despite the availability of prophylactic
vaccines, HBV is estimated to infect approximately 350 million
people and cause 600,000 hepatitis B-related deaths annually
worldwide. The HBV genome is a relaxed circular, partially
double-stranded DNA molecule, surrounded by the HBV core
antigen (HBcAg) and an envelope containing the HBV surface
antigen (HBsAg) [3]. The negative strand has an invariable length
of about 3.5 kb, and the positive strand is shorter than the nega-
tive strand. Following infection, covalently closed circular DNA
(cccDNA) is synthesized and maintained at low copy numbers
in the nuclei of infected hepatocytes; cccDNA serves as the tran-
scription template for all viral RNAs [4]. Thus, cccDNA is respon-
sible for the establishment of viral infection and persistence.
Currently, interferon (IFN)–a is used for hepatitis B therapy,
and IFN-a treatment can result in virus clearance in some cases,
but its efficacy is limited, and most patients cannot tolerate high
doses [5,6]. Other clinically available HBV drugs are nucleoside or
nucleotide analogues that inhibit the viral reverse transcriptase16 vol. 64 j 547–555
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(RT), but they reportedly result in viral resistance [7]. Moreover,
RT inhibitors only control HBV infection, but never lead to elim-
ination of HBV because HBV mRNAs derived from cccDNA are
continuously produced even under treatment. Consequently,
novel approaches for the treatment of HBV-infected individuals
are needed. However, the absence of a robust cell culture system
for HBV infection has stymied both virus lifecycle analyses and
drug discovery efforts.
Primary human hepatocytes (PHH) and primary Tupaia
hepatocytes are susceptible to HBV infection, but use of either cell
type is hampered by limited availability of and unpredictable vari-
ability among liver specimens, human or Tupaia [8]. HepaRG cells
are also susceptible to HBV infection, but this susceptibility is
strictly dependent on HepaRG differentiation state [9]. Recently,
sodium taurocholate cotransporting polypeptide (NTCP) has been
identified as a HBV receptor [10]. Although overexpression of
NTCP in HepG2 and HuH7 cells can render these cells able to
support HBV infection and production, NTCP-transfected HepG2
or HuH7 cells are much less efficient model cells than PHH or
primary Tupaia hepatocytes cells.
Here we have used PXB cells, which are primary hepatocytes
derived from chimeric mice with humanized liver tissues [11],
to develop a novel therapy for HBV treatment. PXB cells are sus-
ceptible to HBV infection, and more available and consistent than
PHH cells. To find a cure for HBV infection, we have focused on
short-interfering RNAs (siRNAs) that target HBV-specific RNAs
to suppress production of HBV proteins. Several HBV proteins
have been shown to downregulate the adaptive immune response
to HBV [12,13]. Elimination of HBV proteins may be overcome by
suppression of CD8+ T cell responses in chronic HBV-infected
patients. One of the most challenging issues with siRNA-based
therapies for HBV is targeting the delivery of the siRNAs to
hepatocytes. The siRNA carrier we used is a novel pH-sensitive
multifunctional envelope-type nanodevice (MEND). Previously, a
MEND was able to deliver siRNA specifically to the liver in an ani-
mal model [14]. We have found that selected siRNAs that target
consensus sequences of HBV RNAs, downregulated levels of HBV
DNA, HBsAg and HBeAg in vitro and in vivo. These findings indi-
cated that our approach could be the basis for a novel class of
anti-HBV drug that is superior to RT inhibitors.Materials and methods
Synthesis of compound 2
DLin-ketone was synthesized from linoleic acid as described previously [15].
tert-Butyl diethylphosphonoacetate (2.14 ml, 9.11 mmol) and tBuOK (937 mg,
8.35 mmol) were successively added to dry tBuOH (40 ml); the mixture was
stirred at room temperature (r.t.) for 5 min; DLin-ketone (4.00 g, 7.59 mmol) dis-
solved in dry tBuOH (10 ml) was added. The mixture was refluxed for 3 h and
then concentrated. The residue was dissolved in EtOAc (50 ml), and the organic
layer was washed with saturated NH4Cl (2  50 ml). The organic phase was dried
over anhydrous Na2SO4. Evaporation of the solvent resulted in a yellowish oily
residue. The residue was purified using an automated Teledyne ISCO combiflush
Rf chromatography system (hexane/EtOAc). This process yielded 3.54 g (75%) of
compound 2 as a colorless oil with the following properties: 1H NMR
(500 MHz, CDCl3) d: 5.52 (1H, s), 5.32–5.37 (8H, m), 2.76 (4H, t), 2.53 (2H, t),
1.97–2.09 (10H, m), 1.43 (9H, s), 1.20–1.40 (36H, m), 0.87 (6H, t) ppm.
Synthesis of compound 3
Compound 2 (453 mg, 0.725 mmol) was dissolved in 10% (v/v) of trifluoroacetic
acid in dichloromethane (DCM). The mixture was stirred at r.t. for 4 h. EtOAc548 Journal of Hepatology 201(50 ml) was added to the mixture that was then washed with HCl solution
(1 M, 50 ml  2) and brine (50 ml). The organic phase was dried with Na2SO4.
Evaporation of the solvent gave a pale yellow oily residual crude, which was used
in subsequent experimental steps without further purification.
Synthesis of compound 4 (YSK13-C3)
Compound 3 (3.00 g, 5.28 mmol) was dissolved in DCM (26 ml); DMAP (323 mg,
2.64 mmol) and EDCI (2.53 g, 13.2 mmol) were then added to this solution. The
mixture was stirred for 1 h at r.t., and then 3-(dimethylamino)-1-propanol
(1.54 ml, 13.2 mmol) was added. This reaction mixture was stirred at r.t. over-
night. The reaction mixture was diluted with DCM (100 ml) and washed with
NaOH solution (1 M, 2  100 ml) and brine (100 ml). The organic phase was dried
with Na2SO4, and solvents were removed in vacuo. The crude product was puri-
fied using an automated Teledyne ISCO combiflush Rf chromatography system
(DCM/MeOH). This process yielded 1.90 g of YSK13-C3 as a pale yellow oil with
the following properties: 1H NMR (500 MHz, CDCl3) d: 5.60 (1H, s), 5.29–5.40
(8H, m), 4.10 (2H, t), 2.76 (4H, t), 2.57 (2H, t), 2.33 (2H, t), 2.21 (6H, s), 2.12
(2H, t), 1.97–2.09 (8H, m), 1.81 (2H, m), 1.20–1.45 (36H, m), 0.88 (6H, t) ppm.
Preparation and characterization of MEND/siRNA
The tBuOH dilution method was used to prepare MEND/siRNA. Briefly, a 90%
aqueous tBuOH solution containing YSK13-C3, cholesterol (SIGMA Aldrich, St.
Louis, MO), and mPEG2k-DMG (NOF Corporation, Tokyo, Japan) (molar ratio:
70/30/3) was mixed with siRNA solution in a ratio of 2:1 (v/v). The lipid/siRNA
solution was diluted in 20 mM citrate buffer (pH 4.0) with vigorous mixing.
Ultrafiltration was used to remove the tBuOH, adjust the pH to 7.4, and concen-
tration the products. DiI- or DiD-labeled MEND was prepared by adding DiI or DiD
(0.5 mol% of total lipid, Invitrogen, Carlsbad, CA, USA) to the lipid mixture. Size
and polydispersity of the MEND/siRNA were measured using a Zetasizer Nano
ZS ZEN3600 instrument (Malvern Instruments, Worchestershire, UK). Ribogreen
(Molecular Probes, Eugene, OR, USA) was used to determine the total siRNA con-
centration and the ratio of encapsulated siRNA to total siRNA. A negatively
charged fluorescent dye 6-(p-toluidino)-2-naphthalenesulfonic acid (TNS) (Wako
Chemicals, Osaka, Japan) was used to measure the apparent pKa of the MEND.
Evaluation of F7 gene silencing activity
MEND/siF7 at the indicated doses was intravenously administered to ICR mice
(Japan SLC, Shizuoka, Japan). Mice were anesthetized 48 h after siRNA treatment,
and blood samples were collected via cardiac puncture and processed to plasma
with heparin. Biophen F7 chromogenic assay kits (Aniara Corporation) were used
according to the manufacturer’s protocol to measure plasma F7 activity.
Evaluation of biodistribution
DiD-labeled MEND/siRNA was administered to ICR mice at a dose of 0.5 mg/kg
ICR. Liver, lung, spleens, and kidneys were collected 30 min after treatment; a
Precellys 24 was used to homogenize each tissue sample in 1% sodium dodecyl-
sulfate solution. VatioskanFlash (Thermo Scientific) was used to measure the
fluorescence intensity at kex = 648 nm and kem = 669 nm of each homogenate.
Observation of intrahepatic distribution
DiI-labeled MEND/Cy5-labeled siRNA was administered to ICR mice at a dose of
1 mg/kg. Each treated mouse was then injected with 40 lg FITC-conjugated Iso-
lectin B4 (Vector Laboratories, Burlingame, CA, USA) 25 min after MEND treat-
ment, and liver tissues were collected 30 min after MEND treatment.
Hoechst33342 (Dojindo Laboratories, Kumamoto, Japan) was used to stain cell
nuclei in liver specimens; a Nikon A1 (Nikon Co. Ltd., Tokyo, Japan) was then used
to visualize the intrahepatic distribution of the MEND/siRNA. Images were
captured with a 20 objective.
Preparation of siRNA for HBV knockdown
Each siRNA was designed to target sequences that are highly conserved among
HBV 17 strains (Genotype A: AB246338, AY161149, X51970, AM282986,
AF297621, Genotype B: AB246341, AB073858, AB033554, D00329, D00330,
AF100309, Genotype C: AB246345, AB048704, AB014381, AY123041,6 vol. 64 j 547–555
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AB033556, AB231908). Chemically synthesized HBV-siRNAs and a control siRNA
were purchased from Invitrogen (Carlsbad, CA, USA) and Thermo Scientific (Wal-
tham, MA, USA), respectively. The sequences of theses siRNAs were:
50-UUGAGAGAAGUCCACCACGAGUCUA-30 (si249),
50-AAUUGAGAGAAGUCCACCACGAGUC-30 (si251),
50-UCAAGAUGUUGUACAGACUUGGCCC-30 (si758),
50- CAGAGGUGAAGCGAAGUGCACACGG-30 (si1575),
50-GUGAAAAAGUUGCAUGGUGCUGGUG-30 (si1804),
50-UUUCCGGAAGUGUUGAUAAGAUAGG-30 (si2312),
50-UAAAGUUUCCCACCUUAUGAGUCCA-30 (si2460)
50-CUAAUACAGGCCAAUACAUUU-30 (Negative control siRNA) (only the anti-
sense strands are shown).
The HBV-siRNAmix was a mixture comprising equal moles of individual siR-
NAs; HBV-siRNAmix was prepared from si251, si1804, and si2312.
Primary human hepatocytes (PXB cells)
A monolayer of primary human hepatocytes derived from chimeric mice with
human liver were obtained from PhoenixBio Co., Lid (Hiroshima, Japan) and
grown in collagen-coated plates (Corning Life Science, Tewksburry, MA, USA)
[11,16,17]. Hepatocytes were cultured in dHCGM medium consisting of Dul-
becco’s modified Eagle’s medium (DMEM; Life Technologies, Grand Island, NY,
USA) with 10% fetal bovine serum (FBS; JRH Biosciences, Lenexa, KS, USA),
20 mM HEPES (Life Technology), 44 mM NaHCO3, antibiotics (100 U/ml penicillin
G and 100 lg/ml streptomycin, Grand Island, NY, USA), 15 lg/ml L-proline
(Wako, Osaka, Japan), 0.25 lg/ml Insulin (SIGMA, St Louis, MO, USA), 50 nM dex-
amethazone (SIGMA), 5 ng/ml epidermal growth factor (Millipore, Bedford, MA,
USA), 0.1 mM L-ascorbic acid (Wako), and 2% dimethyl sulfoxide (SIGMA).Preparation of HBV inoculum and infection in vitro
Sera for HBV inocula were obtained from chimeric mice infected with HBV-
containing culture medium (genotypes: Ae_JPN, Bj_JPN35, and C_JPNAT; acces-
sion numbers: AB246338, AB246341, and AB246345, respectively). SMITEST
EX-R&D (MBL; Medical & Biological laboratories Co., LTD, Nagano, Japan) was
used to isolate HBV DNA from sera, and HBV DNA copy number/sample was
determined by real-time PCR. Primary hepatocytes were infected with HBV at
5-genome equivalents (Geq)/cell in the presence of 4% polyethylene glycol
8000 (PEG8000, Promega, Madison, WI, USA). Inoculated cells were washed 1
and 2 days after infection; medium was harvested every 5 days after that.In vitro HBV suppression assay
MEND/siRNAs were diluted in FBS and then mixed with dHGCM medium that
contained 20% FBS. After 24 h treatment, the medium was replaced with dHCGM.
Baraclude (Entecavir; ETV, Bristol-Myers Squibb, NY, USA) was dissolved in
DMSO; this solution was added to the dHCGM during the examination.DNA extraction and quantification of HBV DNA
SMITEST EX-R&D was used to extract HBV DNA from either 30 ll of culture
medium or 1 ll of humanized-mouse serum. SMITEST EX-R&D was also used
according to the manufacturer’s instructions to extract intracellular HBV DNA
from cell lysates. Quantification of HBV DNA was performed as described
previously [18]. The mean value and standard deviation of three independent
experiments are shown. The mean value of each control siRNA-treated or
untreated sample was defined as the baseline.
Detection of HBsAg and HBeAg
Supernatants of cultures were harvested 7 and 14 days after treatment with
MEND/HBV-siRNAs, MEND/HBV-siRNAmix, or entecavir. In treatment of MEND/
HBV-siRNAs, supernatants of three independent experiments were pooled. Sera
of chimeric mice were collected one day before and 1, 3, 5, 7, 10 and 14 days after
MEND/HBV-siRNAmix treatment. Each supernatant sample was diluted 15-fold
with saline. Each sera sample was diluted 300 or 600-fold with saline. Architect
HBsAg QT and Architect HBeAg QT (Abbott Japan Co., Ltd., Tokyo) in SRL, Inc.Journal of Hepatology 201(Tokyo, Japan) were used to measure HBsAg and HBeAg, respectively, in each
supernatant or sera sample (Tokyo, Japan). The mean values and standard devia-
tions of three independent experiments are shown. The mean value of each con-
trol siRNA or untreated sample was defined as the baseline.
Generation of chimeric mice infected with HBV
Chimeric mice infected with HBV were prepared as previously described [19]. In
brief, human hepatocytes were transplanted into uPA+/+/SCID mice in PhoenixBio
(Hiroshima, Japan) [11]. Then mice aged more than 12 weeks were injected with
sera from chimeric mice infected with HBV (Genotype C_JPNAT, 1x106 copies per
dose). Kinetics of virus titers in sera were observed for 42 days. At the time of ETV
or MEND/HBV-siRNAmix administration, serum levels of HBV genomic DNA were
1.5  109 to 5.6  109 or 3.3  107 to 9.1  108 copies/ml, respectively.Treatment of chimeric mice
Chimeric mice infected with HBV each were randomly allocated into four groups
(Genotype A MEND/HBV-siRNAmix; n = 2, MEND/control siRNA; n = 3, Genotype
C MEND/HBV-siRNAmix; n = 3, MEND/control siRNA; n = 2 ETV; n = 5, Untreated;
n = 5). Starting on day 0, mice were given a single intravenous dose of MEND/
HBV-siRNAmix or MEND/control siRNA (5 mg/kg). ETV was dissolved in DMSO
and then diluted with saline to 3 lg/ml. The dose formulation of ETV was admin-
istered to five mice via oral gavage once a day (30 lg/kg). Human serum albumin
in the blood was measured using Alb-II kit (Eiken Chemical, Tokyo, Japan) accord-
ing to the manufacturer’s instructions.Results
Development of optimal MEND/siRNA for hepatocytes
The capacity of an siRNA carrier to escape from the endosomal
compartment is important for efficient siRNA delivery to hepatic
tissue [20]. In a previous study, we developed a pH-sensitive
cationic lipid, designated YSK05, which exhibited higher fuso-
genic activity with biomembranes than conventional lipids, and
it mediated higher gene silencing activity [21]. Here, we designed
a new pH-sensitive cationic lipid, designated YSK13-C3, to fur-
ther improve gene silencing activity in hepatocytes. YSK13-C3
was synthesized from DLin-ketone in 3 steps (Fig. 1A). The MEND
used in this study was formulated using YSK13-C3, cholesterol,
mPEG2k-DMG, and siRNA in a tBuOH dilution procedure. The
mean diameter of the MENDs was 75 nm, and the MEND size
distribution was narrow (polydipersity: 0.08). The in situ pKa
analysis using a TNS indicated that the apparent pKa of the
MENDs was 6.45, which is within the optimal range for hepatic
gene silencing in vivo [22]. To evaluate the gene silencing activity
with this MEND, siRNA targeting coagulation factor 7 (siF7) was
formulated with the MEND and intravenously injected to mice.
Dose-dependent F7 silencing was observed (Fig. 1B), and the
ED50 (the dose that causes 50% gene silencing) was 0.015 mg/
kg, which is approximately 4-fold less than for YSK05-MEND. A
biodistribution study revealed that more than 80% of the MEND
accumulated in the liver, and only around 1% of the MEND was
detected in any other single tissue including lung, spleen, or kid-
neys (Fig. 1C). We also examined the intrahepatic distribution of
MEND/siRNA. In this experiment, the lipid membrane and siRNA
were labeled with DiI and Cy5, respectively. Both MEND lipid and
the siRNA had accumulated throughout liver tissue (Fig. 1D), and
for the most part, MEND lipid and siRNA colocalized. These
results indicated that the MEND that contained YSK13-C3 specif-
ically accumulated in liver and exhibited efficient hepatic gene
silencing with a single dose.6 vol. 64 j 547–555 549
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Fig. 1. Development of a new pH-sensitive cationic lipid YSK13-C3 and
characterization of MEND/siRNA. (A) Synthesis of YSK13-C3. Reagents; (i) 1,
tert-butyl diethylphosphonoacetate, tBuOH, tBuOK; (ii) TFA/DCM 1/9; (iii)
3-(dimethylamino)-1-propanol, EDC, DMAP, DCM. (B) Dose-dependent F7 gene
silencing activity of MEND/siF7 in normal mice. (C) Quantification of biodistri-
bution of MEND/siRNA. Lipid membrane of MEND was labeled with DiD. (D)
Observation of intrahepatic distribution of MEND/siRNA. Lipid membrane and
siRNA were labeled with DiI and Cy5, respectively.
Research ArticlePreparation of siRNAs that target HBV mRNA
HBsAg was translated from 2.1 and 2.4 kb transcripts, and HBeAg
was derived from 3.5 kb transcripts (Fig. 2A). In order to reduce
the amounts of HBsAg and HBeAg, we prepared seven siRNAs that
targeted highly conserved regions of HBV mRNAs. The si249,
si251, and si758 were designed to target 2.1, 2.4, and 3.5 kb tran-
scripts. Target sequences of si1575 and si1804 were located in all
transcripts, whereas those of si2312 and si2460 were located in
3.5 kb transcript. Indeed, the six siRNAs completely matched
the viral sequence used in this experiment (Fig. 2B).
MEND/HBV-siRNA reduces the HBV antigens and HBV DNA in vitro
We developed an in vitro assay system to evaluate the suppres-
sive effect of MEND/HBV-siRNA on HBV antigens. PHH designated
PXB cells were derived from chimeric mice with humanized liver;
PXB cells were seeded into culture plates and infected with HBV
at 5 Geq/cell (Fig. 3A). HBV genotypes A, B, and C were propa-
gated for more than 40 days in these cell cultures (Fig. 3B). Quan-
tification of HBV DNA demonstrated that this culture system was
suitable for the maintenance of long-term HBV infection, which
would mimic chronic infection in patients.
The persistently infected cells were treated with the indicated
MEND/HBV-siRNAs or a MEND/control siRNA for 24 h, and the
amounts of HBsAg and HBeAg in mediumwere measured on days
7 and 14 (Fig. 3C, D). HBsAg levels in culture supernatant were550 Journal of Hepatology 201reduced by each of three siRNAs (si251, si1575, or si1804) for
cells infected with genotype A, B, or C; moreover, these suppres-
sive effects of the MEND/HBV-siRNAs continued for 14 days. In
contrast, the two siRNAs (si2312 and si2460) that targeted sites
located outside of the transcribed region of HBsAg had no sup-
pressive effects on HBsAg levels for cells infected with A, B, or
C. HBeAg levels in culture supernatant were reduced by each of
five siRNAs (si251, si1575, si1804, si2312, or si2460) for cells
infected with genotype A or C (Fig. 3D). HBeAg of genotype B
could not be detected in this study, which depended on the Archi-
tect HBeAg QT (Abbott Japan Co., Ltd., Tokyo) assay. These results
indicated that individual siRNAs that targeted different HBV
mRNA led to a reduction of the respective antigen, HBsAg or
HBeAg, and that these suppressive effects persisted for 14 days.
A HBV transcript is used as a template for synthesis of geno-
mic HBV DNA. In addition, RT itself is translated from the full-
length HBV transcript. Thus, we next investigated whether
MEND/HBV-siRNAs affected HBV DNA amount. HBV-DNAs in
the supernatant were reduced by si251, si1575, si1804, si2312,
or si2460 siRNAs in the supernatant of the cells infected with
genotype A, B or C (Fig. 3E). These results indicated that a single
dose of the MEND/HBV-siRNAs could reduce the amount of HBV
DNA and the amount of HBV antigens for 14 days.Mixture of siRNAs leads to efficient and simultaneous reduction of
both HBV antigens and of HBV DNA in vitro
Viruses replicated via RT are subject to high mutation rates
[23–25]. In the present study, in order to prevent emergence of
escaped mutant viruses, we prepared a MEND/HBV-siRNAmix
that contained three siRNAs (si251, si1804, and si2312), each tar-
geted to a different transcribed region. The suppressive effect of
the MEND/HBV-siRNAmix on both HBV antigens and on HBV
DNA levels was evaluated in vitro (Fig. 4A). Primary hepatocytes
were treated with MEND/HBV-siRNAmix for 24 h. Additionally,
to compare the effects of MEND/HBV-siRNAmix on HBV, parallel
cell cultures were treated with ETV for 14 days. Rapid and effi-
ciently reductions of HBsAg and HBeAg in the supernatant were
observed with a single treatment of MEND/HBV-siRNAmix
(Fig. 4B). HBsAg levels were suppressed to less than 9% of non-
treated levels by administration of 22.5 nM MEND/HBV-
siRNAmix. MEND/HBV-siRNAmix dramatically reduced HBeAg
by day 7. In contrast, ETV did not efficiently reduce the amounts
of HBsAg or HBeAg in vitro (Fig. 4B), but ETV did significantly
reduce HBV DNA amounts (Fig. 4C, D). Suppressive effects of a sin-
gle dose of MEND/HBV-siRNAmix on extracellular and intracellu-
lar levels of HBV DNA were comparable to those of ETV for 7 days.
These results indicated that MEND/HBV-siRNAmix could reduce
the amount of HBV antigens as well as that of viral DNA. In con-
trast, ETV had little ability to reduce HBV antigens in vitro.MEND/HBV-siRNAmix leads to decreased levels of both HBV DNA and
HBV antigens in vivo
Because the MEND/HBV-siRNAmix suppressed the production of
viral antigens in primary hepatocytes, we evaluated the effects of
this treatment on HBV antigens in vivo. Before conducting the
experiment, we analyzed viral proliferation in chimeric mice.
On 4 weeks post-infection, viral proliferation approached a pla-
teau (Fig. 5B). Chimeric mice persistently infected with HBV were
given a single intravenous dose of MEND/HBV-siRNAmix6 vol. 64 j 547–555
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Genotype B:-------------------------
Genotype C:-------------------------
si1804: 3’-GUGGUCGUGGUACGUUGAAAAAGUG-5’
5’-CACCAGCACCAUGCAACUUUUUCAC-3’
Genotype A:-------------------------
Genotype B:-------------------------
Genotype C:-------------------------
si2312: 3’-GGAUAGAAUAGUUGUGAAGGCCUUU-5’
5’-CCUAUCUUAUCAACACUUCCGGAAA-3’
Genotype A:-------------------------
Genotype B:-------------------------
Genotype C:-------------------------
si758: 3’-CCCGGUUCAGACAUGUUGUAGAACU-5’
5’-GGGCCAAGUCUGUACAACAUCUUGA-3’
Genotype A:----------------G----G---
Genotype B:-------------------------
Genotype C:-------------------------
Genotype A: Ae_JPN
Genotype B: Bj_JPN35
Genotype C: C_JPNAT
Fig. 2. Selection of siRNA targeting HBV mRNAs. (A) Conservation of HBV sequences and target regions for siRNAs. The conservation rate of nucleotide sequences was
calculated based on sequences from 16 strains (each genotype A, B, or C). Seven siRNA target sequences were selected from highly conserved regions. Numbering of HBV
bases begins with position 1 at the EcoRI site. (B) Alignment of HBV sequences in siRNAs target regions. Dashed lines indicate identical nucleotides among siRNA target
sequences.
JOURNAL OF HEPATOLOGY(Fig. 5A). The levels of HBsAg and HBeAg were rapidly reduced by
a single dose of MEND/HBV-siRNAmix, and these suppressive
effects continued for 14 days (Fig. 5C). Furthermore, HBV DNA
levels in sera were reduced (Fig. 5D). MEND/HBV-siRNAmix-
treated mice did not exhibit decrease human albumin levels
(Fig. 5E). These results indicated that a single administration of
MEND/HBV-siRNAmix could efficiently suppress the levels of
HBV antigens as well as those of HBV DNA in vivo.
A reverse transcriptase inhibitor does not effectively suppress HBV
antigens
The RT inhibitor ETV can reduce the amount of HBV DNA in sera
of HBV-infected patients, but ETV has only a small effect on HBV
antigen levels [26]. Here, we evaluated the anti-HBV effects of
ETV in chimeric mice with humanized liver tissue that was
chronically infected with HBV genotype C (Fig. 5A). Although
daily administration of ETV reduced the amount of HBV DNA in
the sera of these mice, no efficient reduction of HBsAg or HBeAgJournal of Hepatology 201was observed even when ETV was administered for 35 days
(Fig. 5F). These results are consistent with the previous findings
that ETV does not efficiently decrease HBsAg levels in HBV-
infected patients [26].Discussion
Pegylated-IFN (Peg-IFN) and RT inhibitors such as ETV have been
used for the treatment of HBV. Peg-IFN can reduce the amount of
viral antigens and DNA [27]. However, the antiviral effect of Peg-
IFN is limited, and side effects are observed in patients treated
with Peg-IFN. The point of action of ETV is the RT process; conse-
quently, ETV is not expected to reduce the amounts of viral pro-
teins. Indeed, little reduction of viral antigens was observed in
chimeric mice with humanized liver tissue during 35 days of
daily administration of ETV (Fig. 5F). Here, we aimed to use a
liver-specific drug delivery system, designated MEND, together
with an effective siRNAmix to suppress production of viral6 vol. 64 j 547–555 551
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Fig. 3. Efficacy of MEND/HBV-siRNA containing a single siRNA in primary hepatocytes infected with HBV. (A) Experimental schedule for primary hepatocytes infected
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JOURNAL OF HEPATOLOGYantigens. The MEND/HBV-siRNAmix suppressed HBsAg and
HBeAg levels as well as HBV DNA levels in vitro and in vivo
(Fig. 4B–D, and Fig. 5C, D). Therefore, the MEND/HBV-siRNAmix
was superior to ETV for controlling HBV.
In a previous study, we developed a pH-sensitive cationic
lipid, designated YSK05, and succeeded in efficient F7 gene
silencing in mice (ED50: 0.06 mg/kg) [14,21]. However, improve-
ment of efficiency of endosomal escape remains challenging.
Therefore, we designed a new pH-sensitive cationic lipid, desig-
nated YSK13-C3, based on the following strategies to improveJournal of Hepatology 201the efficiency of endosomal escape. First, YSK13-C3, like YSK05,
has two long and unsaturated acyl chains to enhance the bulki-
ness of the hydrophobic region. Second, a double bond between
acyl chains and an ester linker were also included to enhance
the bulkiness of the hydrophobic region; notably, the bond angle
of sp2 carbon was fixed at 120, which is larger than that of an sp3
carbon (109.5). Also, an ester bond was chosen as the linker
between hydrophobic region and the amine moiety to ensure
that the MEND would be biodegradable. As expected, the MEND
containing YSK13-C3 achieved strong F7 gene silencing
(ED50: 0.015 mg/kg), which is approximately 4-fold more
efficient compared to that previously reported for YSK05-MEND
[14]. The MEND containing YSK13-C3 specifically accumulated
in liver, and its distribution throughout the liver was uniform.
Also, observation of intrahepatic distribution of dual-labeled
MEND demonstrated that siRNA and MEND lipid were localized
in a uniform way and were almost always colocalized, indicating
that the MEND/HBV-siRNAmix was taken up by most hepato-
cytes as an entire particle. These results indicated that the MEND
containing YSK13-C3 was a suitable siRNA carrier for treatment
of HBV infection.
RNA interference (RNAi) is based on the nucleotide sequence
similarity between the siRNA and the target mRNA, and RNAi
can be used to inhibit HBV replication in vitro and in vivo [28].
However, viruses that have a RT reaction in the life cycle are cap-
able of producing escape mutations [23–25]. Additionally,
although RNAi therapy with an effective drug delivery system
for liver tissue has been reported, it was necessary to chemically
modify the siRNA with cholesterol or saccharide [28]. To prevent
the emergence of escape mutations, we prepared a mixture of
three siRNAs that each targeted a different region of HBV gen-
ome. In addition, since MEND-siRNA particles were produced
by simply encapsulating the siRNA within the MEND, it should
be possible to easily obtain custom MEND-siRNA units that are
optimized for individual patients. Furthermore, since the MEND
encapsulates nucleic acids within the lipid membranes, the phys-
ical properties of the MEND are not affected by the type of the
nucleic acids. The nucleic acids which can be delivered by the
MEND are not restricted only to siRNA, and the MEND can effi-
ciently deliver various kinds of nucleic acids including antisense
oligonucleotides and plasmid DNAs (pDNAs) as well as siRNAs to
hepatocytes. Indeed, we previously succeeded in efficient
delivery of the anti-microRNA oligonucleotides against
microRNA-122 to hepatocytes in vivo, and recently reported that
intravenous administrations of the MEND encapsulating pDNA
coding HBV 50-e region-derived RNA successfully abolished the
HBV replication through induction of type III interferons in
chimeric mice with humanized liver tissue [29]. Therefore, the
MEND system would be able to deliver these various nucleic
acids simultaneously to hepatocytes and offer the multi-target
therapy against HBV infection.
HBsAg is translated from 2.1 and 2.4 kb mRNAs, and HBeAg is
translated from a 3.5 kb full-length mRNA [30]. No reduction of
HBsAg was observed following treatment with si2312 or si2460
(Fig. 3C), indicating that it is necessary to prepare siRNAs, which
target mRNAs that encode each virus antigen. In contrast, HBeAg
is translated from a 3.5 kb mRNA; consequently, each perfect-
matching siRNAs reduced it (Fig. 3D). In addition, HBV DNA is
produced from the full-length viral RNA by the viral RT. There-
fore, HBV DNA reductions correlated with HBeAg reductions in
our culture system (Fig. 3D, E).6 vol. 64 j 547–555 553
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Fig. 5. Efficacy of MEND/HBV-siRNAmix in vivo. (A) Experimental schedule for chimeric mice with humanized liver. (B) Viral proliferation of a genotype C virus in
chimeric mice. (C) Relative amounts of HBsAg and HBeAg in sera. (D) Relative amount of HBV DNA. (E) The amounts of human albumin (Alb) in sera. (F) Relative amounts of
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Research ArticleCytotoxic T lymphocytes (CTLs) that specifically target HBV
antigen are responsible for clearing HBV from patients [31]. How-
ever, CTLs do not respond properly in chronically infected
patients [32]. A single dose of MEND/HBV-siRNAmix efficiently
suppressed HBsAg and HBeAg as well as HBV DNA in vivo
(Fig. 5C, D). Because HBV antigens are involved in the suppression
of the immune response [12,13,33–35], effective suppression of
viral proteins could activate HBV-specific acquired immunity
and release from HBV persistence.
Here, we demonstrated that a MEND/HBV-siRNAmix could
control HBV more efficiently than did ETV. The effect of a
single dose of MEND/HBV-siRNAmix continued for a long time,
indicating the burden on the patient would be reduced with554 Journal of Hepatology 201this treatment. Based on these findings, further investigations
involving an animal model of acquired immunity are
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